PUMA BIOTECHNOLOGY, INC.PBYIEarnings & Financial Report

Nasdaq · pharmaceutical industry

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Revenue

$54.5M

Gross Profit

$42.3M

Operating Profit

$9.6M

Net Profit

$8.8M

Gross Margin

77.7%

Operating Margin

17.6%

Net Margin

16.2%

YoY Growth

-32.4%

EPS

$0.17

Financial Flow

PUMA BIOTECHNOLOGY, INC. Q3 2025 Financial Summary

PUMA BIOTECHNOLOGY, INC. reported revenue of $54.5M for Q3 2025, with a net profit of $8.8M (16.2% margin). Cost of goods sold was $12.2M, operating expenses totaled $32.7M.

Key Financial Metrics

Total Revenue	$54.5M
Net Profit	$8.8M
Gross Margin	77.7%
Operating Margin	17.6%
Report Period	Q3 2025

PUMA BIOTECHNOLOGY, INC. Annual Revenue by Year

PUMA BIOTECHNOLOGY, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $230.5M).

Year	Annual Revenue
2024	$230.5M
2023	$235.6M
2022	$228.0M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$72.2M	$43.8M	$47.1M	$80.5M	$59.1M	$46.0M	$52.4M	$54.5M
YoY Growth	9.9%	-17.1%	-13.7%	43.5%	-18.2%	5.1%	11.4%	-32.4%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$230.5M	$214.1M	$205.0M	$220.7M	$213.3M	$196.2M	$194.9M	$202.9M
Liabilities	$177.1M	$163.2M	$156.5M	$149.6M	$121.2M	$99.1M	$90.2M	$87.6M
Equity	$53.4M	$51.0M	$48.5M	$71.1M	$92.1M	$97.1M	$104.7M	$115.3M